As we and others have shown that several cancer stem cell inhibitors target high CD44 cell population and that CD44 is expressed in NEPC, it is tempting to conclude that targeted inhibition of CD44 expressing cells could also prevent the progression of t-NEPC [83,150,151,152,153]. The gene discussed is CD44; the disease is cancer.